Correction: sumatriptan TO THE EDITOR: I am writing to call your attention to a mistake that appeared in the published version of our manuscript "Sumatriptan: A Selective 5-Hydroxytryptamine Receptor Agonist for the Acute Treatment of Migraine" (Ann Pharmacother 1992;26:800-8). Figure 2 was incorrectly referenced as "Adapted from Reference 12, with permission," when, in fact, it should have read "Adapted from Reference 10, with permission." Although we tried to be as careful as possible, we, regrettably, missed this error when perusing the galley proofs of the manuscript. TERENCE RJLLERTON, Pharm.D., BCPS
ClinicalResearchFellow Divisionof Neuropharmacology The Dent Neurologic Institute MillardFillmoreHospital 3 GatesCircle Buffalo, New York 14209
Correction: cyanide toxicity from sodium nitroprusside TO THE EDITOR: I am writing in reference to the article on the risks and management of cyanide toxicity from sodium nitroprusside (Ann Pharmacother 1992;26:515-9). An error exists regarding the administration of the cyanide antidote kit. Following the inhalation of amyl nitrite, intravenous sodium nitrite should be administered, not intravenous amyl nitrite as indicated in steps I and 2 of Table 3. DANJ. HALBERSTADT, B.Pharm.
CriticalCare PharmacySupervisor AbingtonMemorialHospital Clinical1nstructor Philadelphia CollegeofPharmacyand Science Abington,Pennsylvania 19001
TO THE EDITOR: I am writing to point out an error in the article on cyanide toxicity. In the second step of Table 3 , the recommendations for administration of the contents of the cyanide antidote kit incorrectly list "amyl nitrite 300 mg iv... over 2-4 min." The correct drug for this dose is sodium nitrite. The statement should read " ... administer sodium nitrite 300 mg iv over 2-4 min."
The Cyanide Antidote Package (Eli Lilly, Indianapolis) contains amyl nitrite inhalant (0.3 mL, 12 ampules) along with sodium nitrite 3% (two lO-mL ampules) and sodium thiosulfate 25% (two 50-mL ampules).
Step I for treatment of acute cyanide toxicity consists of crushing an amyl nitrite ampul in the enclosed gauze and holding this under the patient's nostril for 15-30 seconds every two to three minutes until the sodium nitrite is administered. An intravenous line should be placed during this process so that the remaining drugs can be administered.
Step 2 consists of administering sodium nitrite 300 mg intravenously (10 mL of 3% solution) over two to four minutes. The pediatric dose is 6-8 mUm 2 or 0.2 mL/kg body weight, not to exceed 10 mL per injection. Step 3 consists of administering sodium thiosulfate 12.5 g intravenously (50 mL of 25% solution) immediately after the administration of sodium nitrite. The pediatric dose is 7 g/m2, not to exceed 12.5 g. Steps 2 and 3 can be repeated at one-half the dose if symptoms reappear,'> Chronic cyanide toxicity secondary to sodium nitroprusside administration is treated by discontinuing the nitroprusside infusion and placing the patient on 100% oxygen. The patient should then receive sodium nitrite and sodium thiosulfate as described above. However, some patients, such as those who are mildly symptomatic or those who may not tolerate clinically significant methemoglobin concentrations, may do well with the discontinuation of the sodium nitroprusside infusion followed by administration of sodium thiosulfate alone.' MICHAEL L. PICCOLO, Pharm.D.
ClinicalPharmacokinetics Resident Departmentof PharmacyServices
University ofPennsylvania MedicalCenter 3400 SpruceStreet Philadelphia. Pennsylvania 19104
